Ginkgo Bioworks Holdings, Inc. (DNA)
NYSE: DNA · Real-Time Price · USD
12.24
-0.11 (-0.89%)
Aug 28, 2025, 10:17 AM - Market open
Ginkgo Bioworks Holdings Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2020 |
| 230.82 | 227.04 | 251.46 | 477.71 | 313.84 | 76.66 | Upgrade | |
Revenue Growth (YoY) | 25.21% | -9.71% | -47.36% | 52.22% | 309.40% | 41.48% | Upgrade |
Cost of Revenue | 48.49 | 44.55 | 54.01 | 204.22 | 129.69 | 15.61 | Upgrade |
Gross Profit | 182.32 | 182.5 | 197.45 | 273.49 | 184.15 | 61.05 | Upgrade |
Selling, General & Admin | 199.42 | 237.15 | 350.66 | 1,403 | 862.95 | 38.31 | Upgrade |
Research & Development | 277.68 | 424.06 | 580.62 | 1,053 | 1,150 | 159.77 | Upgrade |
Operating Expenses | 477.09 | 661.21 | 931.28 | 2,456 | 2,013 | 198.07 | Upgrade |
Operating Income | -294.77 | -478.72 | -733.83 | -2,182 | -1,828 | -137.03 | Upgrade |
Interest Expense | -0.09 | -0.09 | -0.09 | -0.11 | -2.37 | -2.39 | Upgrade |
Interest & Investment Income | 28.75 | 38.61 | 57.22 | 20.26 | 0.84 | 2.58 | Upgrade |
Earnings From Equity Investments | - | - | -2.64 | -43.76 | -77.28 | -0.4 | Upgrade |
Other Non Operating Income (Expenses) | -1.04 | 9.57 | 14.31 | 132.6 | 56.88 | 7.84 | Upgrade |
EBT Excluding Unusual Items | -267.15 | -430.63 | -665.04 | -2,073 | -1,850 | -129.39 | Upgrade |
Merger & Restructuring Charges | -16.05 | -24.17 | -96.21 | -27.9 | - | - | Upgrade |
Impairment of Goodwill | - | -47.86 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | -23.38 | -28.83 | -54.83 | -53.34 | -11.54 | -3.73 | Upgrade |
Gain (Loss) on Sale of Assets | -7.01 | -7.01 | -42.5 | 31.89 | - | - | Upgrade |
Asset Writedown | -5.8 | -5.8 | -25.19 | - | - | - | Upgrade |
Other Unusual Items | 3.3 | -3.21 | -9.17 | 1.26 | 23.83 | 8.29 | Upgrade |
Pretax Income | -316.09 | -547.51 | -892.94 | -2,121 | -1,838 | -124.83 | Upgrade |
Income Tax Expense | -0.9 | -0.48 | -0.07 | -15.03 | -1.48 | 1.89 | Upgrade |
Earnings From Continuing Operations | -315.19 | -547.03 | -892.87 | -2,106 | -1,837 | -126.72 | Upgrade |
Minority Interest in Earnings | - | - | - | 1.44 | 6.6 | 0.11 | Upgrade |
Net Income | -315.19 | -547.03 | -892.87 | -2,105 | -1,830 | -126.61 | Upgrade |
Net Income to Common | -315.19 | -547.03 | -892.87 | -2,105 | -1,830 | -126.61 | Upgrade |
Shares Outstanding (Basic) | 54 | 52 | 49 | 42 | 34 | 32 | Upgrade |
Shares Outstanding (Diluted) | 54 | 52 | 49 | 42 | 34 | 32 | Upgrade |
Shares Change (YoY) | 7.76% | 6.76% | 15.75% | 23.48% | 6.71% | 10.95% | Upgrade |
EPS (Basic) | -5.86 | -10.54 | -18.37 | -50.15 | -53.83 | -3.97 | Upgrade |
EPS (Diluted) | -5.86 | -10.54 | -18.37 | -50.20 | -55.53 | -4.00 | Upgrade |
Free Cash Flow | -274.17 | -382.13 | -336.3 | -304.47 | -310.34 | -193.65 | Upgrade |
Free Cash Flow Per Share | -5.10 | -7.36 | -6.92 | -7.25 | -9.13 | -6.08 | Upgrade |
Gross Margin | 78.99% | 80.38% | 78.52% | 57.25% | 58.68% | 79.64% | Upgrade |
Operating Margin | -127.71% | -210.85% | -291.84% | -456.83% | -582.62% | -178.75% | Upgrade |
Profit Margin | -136.56% | -240.94% | -355.08% | -440.63% | -583.12% | -165.16% | Upgrade |
Free Cash Flow Margin | -118.78% | -168.31% | -133.74% | -63.74% | -98.89% | -252.62% | Upgrade |
EBITDA | -230.79 | -415.7 | -663.33 | -2,140 | -1,799 | -123.16 | Upgrade |
EBITDA Margin | -99.99% | -183.09% | -263.80% | - | - | -160.67% | Upgrade |
D&A For EBITDA | 63.98 | 63.02 | 70.51 | 42.55 | 29.08 | 13.86 | Upgrade |
EBIT | -294.77 | -478.72 | -733.83 | -2,182 | -1,828 | -137.03 | Upgrade |
EBIT Margin | -127.71% | -210.85% | -291.84% | - | - | -178.75% | Upgrade |
Revenue as Reported | 230.82 | 227.04 | 251.46 | 477.71 | 313.84 | 76.66 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.